Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma

PURPOSE: Several studies have evaluated the utility of extrapolating the Calvert formula in calculating carboplatin (CBDCA) dosages in solid tumours; however, data regarding haematological cancers are less. Therefore, we conducted a preliminary study of the utility of extrapolating the Calvert formu...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomono, Ayana, Ito, Kaori, Hayashi, Takahiro, Ando, Maiko, Ando, Yosuke, Tsuge, Masahiro, Okamoto, Akinao, Inaguma, Yoko, Okamoto, Masataka, Emi, Nobuhiko, Yamada, Shigeki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965483/
https://www.ncbi.nlm.nih.gov/pubmed/27324021
http://dx.doi.org/10.1007/s00280-016-3076-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965483/
https://www.ncbi.nlm.nih.gov/pubmed/27324021
http://dx.doi.org/10.1007/s00280-016-3076-9

Ejemplares similares